Download Files:
Parsaclisib (hydrochloride)
$390 – $3,100
Products Details
Product Description
– Parsaclisib hydrochloride (INCB050465 hydrochloride) is a potent, selective and orally active inhibitor of PI3Kδ, with an IC50 of 1 nM at 1 mM ATP. Parsaclisib hydrochloride shows approximately 20000-fold selectivity over other PI3K class I isoforms. Parsaclisib hydrochloride can be used for the research of relapsed or refractory B-cell malignancies[1][2][3].
Web ID
– HY-109068A
Storage Temperature
– 4°C (Powder, stored under nitrogen)
Shipping
– Room Temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C20H23Cl2FN6O2
References
– [1]Shin N, et al. Abstract 2671: INCB050465, a novel PI3Kδ inhibitor, synergizes with PIM protein kinase inhibition to cause tumor regression in a model of DLBCL. Cancer Research. 2015, Aug. 75(15).|[2]Shin N, et, al. Parsaclisib Is a Next-Generation Phosphoinositide 3-Kinase δ Inhibitor with Reduced Hepatotoxicity and Potent Antitumor and Immunomodulatory Activities in Models of B-Cell Malignancy. J Pharmacol Exp Ther. 2020 Jul;374(1):211-222.|[3]Yue EW, et, al. INCB050465 (Parsaclisib), a Novel Next-Generation Inhibitor of Phosphoinositide 3-Kinase Delta (PI3Kδ). ACS Med Chem Lett. 2019 Oct 17;10(11):1554-1560.
CAS Number
– 1995889-48-9
Molecular Weight
– 469.34
Compound Purity
– 98.74
SMILES
– CCOC1=C([C@@H](C2)CNC2=O)C(F)=C(Cl)C=C1[C@@H](N3C4=NC=NC(N)=C4C(C)=N3)C.[H]Cl
Clinical Information
– Phase 3
Research Area
– Cancer
Solubility
– DMSO : 240 mg/mL (ultrasonic)|H2O : 100 mg/mL (ultrasonic)
Target
– PI3K
Isoform
– PI3Kδ
Pathway
– PI3K/Akt/mTOR
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
